U.S. Markets closed

Immunomedics, Inc. (IMMU)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
8.61-0.12 (-1.37%)
At close: 4:00PM EDT
People also watch
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
  • This morning 23 June 2017, I just received a proxy statement from IMMU that they are going to dilute the share price by 57% by selling additional shares. Will increase total number of shares from 160,000,000 to 265,000,000. An increase of 95M shares and dilution of 57%. I received this IMMU share holder statement through my Fidelity account where I own IMMU shares.
  • Didn't expect this much of a pullback
  • Durable Responses Seen With Sacituzumab Govitecan in NSCLC


    Durable Responses Seen With Sacituzumab Govitecan in NSCLC
    The antibody-drug conjugate sacituzumab govitecan was well-tolerated and produced a median duration of response of 6.0 months in previously treated patients with metastatic non–small cell lung cancer.
  • $12 by first Ph3-132 dosing event...perhaps as early as July 10 ( wag). At that point the shorts need an amazingly bad bit of news to reverse momentum. But, in fact, the news will only get better...as we head to FDA sub. near end of year/beginning next.
  • Mini squeeze, starting to break
  • Its moving to 9$ or more by Friday. Buy more the news is good today.
  • Over a million shares have traded in after hours.
  • Immu is going to 15 Dollars y the start of Sept..
  • Perceptive Advisors LLC Takes Position in Immunomedics, Inc. (IMMU)
    Posted by Daniel Jordon on Jun 19th, 2017

    Perceptive Advisors LLC Takes Position in Immunomedics, Inc. (IMMU)
    Perceptive Advisors LLC purchased a new stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 300,060 sh
  • with the additional 100 million shares this may first cause the stock to drop to adjust. trying to sift through all of this as I agree it does not add up. continued thoughts on potential dilution and drop in stock price first?
  • Shareholders voted to dilute? Dumbest vote ever. You WANT a takeover - a buyout - small float. ALL contribute to shareholder win. Dilution means mgmnt. wins and shareholders lose. Bummer for longs.
  • What is timeline for FDA approval? Is anyone thinking this will be approved in 2017?
  • Great week
    stock up 15% for the week
  • Biotechnology Sector Breakout in Progress

    It has been quite a while since Hillary Clinton tweeted about drug pricing and Bernie Sanders made similar threatening comments, resulting in a 25% pullback for the industry company stocks. For those who were caught up in this fiasco who stayed the course it looks like considerable profiting is beginning to take hold.

    Carter Worth, Cornerstone Macro, discusses which biotech stocks to buy amid the breakout. The “Fast Money” traders weigh in.

    Technician sees an even bigger breakout for biotech
    Monday, 19 Jun 2017 | 5:33 PM ET

  • Very easy flip today buy in at 820 range sell at 850 or more. At first I thought it may break 8 but not the case
  • This stock is very strong technically and seems to be in good hands with the big guns.
  • Dangerous game being short here. I'm sure there will be calls today for more $ .
  • I have a feeling IMMU will see a pullback now. What yall think? if you guys have questions you should ask awesome_stock_s. They often respond to my emails which is helpful.
  • Gap to fill 5.50 - coincides with the new share issue. Buy then.